Which of the following is not typically seen with the regimen including docetaxel, carboplatin, trastuzumab, and pertuzumab?

• A. Diarrhea
• B. Fatigue
• C. Constipation
• D. Nausea

Answer: (C)

Constipation is not a typical toxicity of this regimen. This combination—docetaxel, carboplatin, trastuzumab, and pertuzumab—tends to cause gastrointestinal side effects like diarrhea and nausea more than constipation. Docetaxel and platinum agents can irritate the GI tract, leading to diarrhea, while anti-HER2 therapies add a risk of infusion reactions and cardiotoxicity rather than constipation. Constipation, when it occurs, is usually due to factors such as opioid use, dehydration, or decreased mobility, not the characteristic drug-specific effects of this regimen. Therefore, constipation stands out as the item not commonly seen with this treatment.